Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedFooter now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. The notice about lapse in government funding was removed.SummaryDifference0.3%

- Check20 days agoChange DetectedAdded a government funding lapse notice and updated the publications section with a 2024 Blood article citation; the page revision was updated to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedAdds a glossary display option and updates QC metadata to Revision: v3.4.0, while removing older QC wording. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check49 days agoChange DetectedA publication citation in the Publications section (Friedberg et al., Blood 2024) was added and subsequently removed; this does not affect the study design, endpoints, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a comprehensive Locations section listing U.S. states and Canadian provinces. Updated the page to Revision: v3.3.3 and removed the older v3.3.2 location blocks and the HHS Vulnerability Disclosure content.SummaryDifference2%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.